Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04600388 · ClinicalTrials.gov registry record
Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 121
- Enrollment target
NCT04600388: Completed study, sponsored by Theranica.
NCT04600388 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 121 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04600388 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 121 participants
- Enrollment target
Study Summary
Post-marketing, retrospective, observational survey study. Users (menstruating women only) of Nerivio who have used Nerivio at least 4 times between October 2019 and December 2020 will be contacted by email and/or through an app notification and will be asked to complete a 5-minute online anonymous survey assessing satisfaction, effectiveness, and safety. Eligible users will sign an informed consent form (the consent language will appear as the first page of the survey, and participants will click either "agree" or "disagree" to the consent statement; those who click "agree" will proceed to the survey, those who click "disagree" will be brought to an exit page) and complete a survey asking about their satisfaction with Nerivio and the effectiveness and safety of the device for acute treatment of menstrual migraine. During the survey, participants will be screened to verify that they have menstrual migraine (self-reported) and have used Nerivio to treat menstrual migraines.
Primary Outcome
Efficacy of Nerivio for headache relief during menstrual migraines rated on a 5-point Likert scale (1 - Not at all effective, 2 - Slightly effective, 3 - Moderately effective, 4 - Very effective, 5- Extremely effective)
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2020-11-10 |
What the finished NCT04600388 record still lists
NCT04600388 is an observational study that tracks outcomes without assigning an intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT04600388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04600388 about?
NCT04600388 is a clinical study titled "Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine". Post-marketing, retrospective, observational survey study. Users (menstruating women only) of Nerivio who have used Nerivio at least 4 times between October 2019 and December 2020 will be contacted by email and/or through an app notification and will be asked to complete a 5-minute online anonymous ...
What is the current status of trial NCT04600388?
This trial is currently completed. The enrollment target is 121 participants. The study started on 2020-09-09. Estimated completion is 2020-11-10.
What interventions are being tested in trial NCT04600388?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT04600388?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI